Oxford Sciences Innovation plc 4
4 · Vaccitech plc · Filed May 6, 2021
Insider Transaction Report
Form 4
Vaccitech plcVACC
Oxford Science Enterprises plc
10% Owner
Transactions
- Conversion
Ordinary Shares
2021-05-04+4,832,142→ 4,832,142 total - Conversion
Ordinary Shares
2021-05-04+1,704,444→ 6,536,586 total - Conversion
Ordinary Shares
2021-05-04+1,661,184→ 8,197,770 total - Purchase
American Depositary Shares
2021-05-04$17.00/sh+600,000$10,200,000→ 8,797,770 total - Conversion
Ordinary Shares
2021-05-04−4,832,142→ 0 total→ Ordinary Shares (4,832,142 underlying) - Conversion
Series A redeemable convertible preferred shares
2021-05-04−1,704,444→ 0 total→ Ordinary Shares (1,704,444 underlying) - Conversion
Series B preferred shares
2021-05-04−1,661,184→ 0 total→ Ordinary Shares (1,661,184 underlying)
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share.
- [F2]Each American Depositary Share represents one ordinary share.
- [F3]Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the "Issuer") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date.
- [F4]The number of shares reported reflects the conversion set out in Footnote (3).